Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Malignant Lymphoma

Free Subscription Articles published in Br J Dermatol Retrieve available abstracts of 57 articles: HTML format

Single Articles

April 2024
1. BLANCHARD M, Morren MA, Busschots AM, Hauben E, et al
   Paediatric onset lymphomatoid papulosis: results of a multicentre retrospective cohort study, on behalf of the EORTC Cutaneous Lymphoma Tumours Group (CLTG).
   Br J Dermatol. 2024 Apr 10:ljae150. doi: 10.1093.
   PubMed     Abstract available
   
   
   
2. ROCCUZZO G, Calvao J, Dobos G, Morsia E, et al
   Cutaneous T-cell lymphoma care across Europe: insights from the Horizon Project.
   Br J Dermatol. 2024 Apr 5:ljae145. doi: 10.1093.
   PubMed    
   
   
   February 2024
3. STAMMLER R, Ta VA, Cohen E, Ram-Wolff C, et al
   Failure of second challenge with Mogamulizumab in CCR4-positive cutaneous T-cell lymphoma.
   Br J Dermatol. 2024 Feb 23:ljae085. doi: 10.1093.
   PubMed    
   
   
   
4. JUNG JM, Cho HS, Kim GH, Won CH, et al
   Psoriasiform mycosis fungoides: a clinical and prognostic retrospective cohort study.
   Br J Dermatol. 2024;190:432-434.
   PubMed    
   
   
   January 2024
5. TRUM NA, Chen L, Zain J, Rosen ST, et al
   Significant survival disparity in Black patients with cutaneous lymphoma: a retrospective cohort study.
   Br J Dermatol. 2024 Jan 29:ljae039. doi: 10.1093.
   PubMed    
   
   
   October 2023
6. 
   Multiple skin lesions, especially on the legs, predict a poorer prognosis in skin lymphoma with large tumour cells.
   Br J Dermatol. 2023;189:e98.
   PubMed    
   
   
   
7. 
   The effect of extracorporeal photopheresis on cytokines released by leukaemic cutaneous T-cell lymphoma.
   Br J Dermatol. 2023;189:e97.
   PubMed    
   
   
   September 2023
8. WEINER D, Ly A, Talluru S, Munjal A, et al
   Efficacy of single-agent chemotherapy with pegylated liposomal doxorubicin or gemcitabine in a diverse cohort of patients with recalcitrant cutaneous T-cell lymphoma.
   Br J Dermatol. 2023 Sep 1:ljad311. doi: 10.1093.
   PubMed    
   
   
   August 2023
9. MIYAGAKI T, Inoue N, Kamijo H, Boki H, et al
   Prognostic factors for primary cutaneous anaplastic large cell lymphoma: a multicenter retrospective study from Japan.
   Br J Dermatol. 2023 Aug 4:ljad266. doi: 10.1093.
   PubMed     Abstract available
   
   
   July 2023
10. PILERI A, Pimpinelli N
    The role of the immune system in cutaneous T-cell lymphoma, an area requiring more investigation.
    Br J Dermatol. 2023 Jul 24:ljad255. doi: 10.1093.
    PubMed    
    
    
    
11. 
    An oncogene-targeted therapy for Merkel cell carcinoma.
    Br J Dermatol. 2023;189:e33.
    PubMed    
    
    
    
12. WAN J, Shin DB, Syed MN, Abuabara K, et al
    Malignancy risk in patients with atopic dermatitis: a population-based cohort study.
    Br J Dermatol. 2023;189:53-61.
    PubMed     Abstract available
    
    
    
13. TSAI YC, Schlaepfer T, Ignatova D, Chang YT, et al
    Boost of innate immunity cytokines as biomarkers of response to extracorporeal photopheresis in leukaemic cutaneous T-cell lymphoma patients.
    Br J Dermatol. 2023 Jul 6:ljad220. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2023
14. ALONSO-ALONSO R, Rodriguez M, Garcia-Diaz N, Tomas-Roca L, et al
    NanoString analysis of mycosis fungoides reveals individual molecular identity.
    Br J Dermatol. 2023;188:812-814.
    PubMed    
    
    
    
15. PETERKNECHT E, Scarisbrick J
    Skin Swabs in the Skin Lymphoma Clinic - From Swab to Treatment.
    Br J Dermatol. 2023 May 13:ljad160. doi: 10.1093.
    PubMed    
    
    
    March 2023
16. FAN K, Srinivas N, Kubat L, Gravemeyer J, et al
    B-cell lymphoma extra-large (Bcl-xL) is a promising drug target in Merkel cell carcinoma.
    Br J Dermatol. 2023 Mar 30:ljad099. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2023
17. BROWN-KORSAH JB, Omar D, Wang X, Taylor SC, et al
    Factors contributing to time to chemotherapy, immunotherapy and radiation for patients with mycosis fungoides in the United States National Cancer Database.
    Br J Dermatol. 2023;188:299-301.
    PubMed    
    
    
    January 2023
18. OYMANNS M, Daum-Marzian M, Bellm A, Elsayad K, et al
    Near complete responses to concurrent brentuximab vedotin and ultra-hypofractionated low-dose total skin electron beam radiation in advanced cutaneous T-cell lymphoma.
    Br J Dermatol. 2023;188:145-146.
    PubMed    
    
    
    November 2022
19. BONTOUX C, de Masson A, Thonnart N, Ram-Wolff C, et al
    Large-cell transformation is an independent poor prognostic factor in Sezary syndrome: analysis of 117 cases.
    Br J Dermatol. 2022;187:815-817.
    PubMed    
    
    
    August 2022
20. KEMPF W
    Follicular T helper cells and cutaneous T-cell lymphomas.
    Br J Dermatol. 2022 Aug 31. doi: 10.1111/bjd.21839.
    PubMed    
    
    
    
21. 
    Better understanding about the severity of disease in cutaneous T-cell lymphoma from studying immune checkpoint receptors.
    Br J Dermatol. 2022;187:e69-e76.
    PubMed    
    
    
    
22. DI RAIMONDO C, Rubio-Gonzalez B, Palmer J, Weisenburger DD, et al
    Expression of immune checkpoint molecules programmed death protein 1, programmed death-ligand 1 and inducible T-cell co-stimulator in mycosis fungoides and Sezary syndrome: association with disease stage and clinical outcome.
    Br J Dermatol. 2022;187:234-243.
    PubMed     Abstract available
    
    
    
23. JIANG TT, Kruglov O, Geskin L, Akilov OE, et al
    Repetitive expanded T-cell receptor clonotypes impart the classic T helper 2 Sezary cell phenotype.
    Br J Dermatol. 2022;187:265-267.
    PubMed     Abstract available
    
    
    
24. BUECHLER CR, Sagher E, Tisack A, Jacobsen G, et al
    Demographic factors and disparate outcomes in mycosis fungoides: retrospective analysis of a racially diverse 440-patient cohort from Detroit, Michigan, USA.
    Br J Dermatol. 2022;187:246-248.
    PubMed    
    
    
    July 2022
25. WANG L, Rocas D, Dalle S, Sako N, et al
    Primary cutaneous peripheral T-cell lymphomas with a T follicular helper phenotype: An integrative clinical, pathological, and molecular case series study.
    Br J Dermatol. 2022 Jul 27. doi: 10.1111/bjd.21791.
    PubMed     Abstract available
    
    
    
26. ROCCUZZO G, Fava P, Avallone G, Aquino C, et al
    Time to next treatment and safety assessment in Cutaneous-T-cell lymphomas: a retrospective analysis on patients treated with bexarotene and acitretin.
    Br J Dermatol. 2022 Jul 13. doi: 10.1111/bjd.21772.
    PubMed    
    
    
    
27. WANG J, Ram-Wolff C, Dobos G, Al Hage J, et al
    Head and neck granulomatous rash associated with mogamulizumab mimicking mycosis fungoides.
    Br J Dermatol. 2022;187:129-131.
    PubMed    
    
    
    June 2022
28. BATTESTI G, Ram-Wolff C, Dobos G, Aubin F, et al
    Granulomatous slack skin: clinical characteristics, prognosis, and response to therapy. A study from the Cutaneous Lymphoma French Study Group.
    Br J Dermatol. 2022 Jun 6. doi: 10.1111/bjd.21699.
    PubMed    
    
    
    
29. ROELENS M, de Masson A, Andrillon A, Ram-Wolff C, et al
    Mogamulizumab induces long-term immune restoration and reshapes tumour heterogeneity in Sezary syndrome.
    Br J Dermatol. 2022;186:1010-1025.
    PubMed     Abstract available
    
    
    May 2022
30. MARTIN-MORO F, Martin-Rubio I, Garcia-Vela JA
    TRBC1 expression assessed by flow cytometry as a novel marker of clonality in cutaneous alphabeta T-cell lymphomas with peripheral blood involvement.
    Br J Dermatol. 2022 May 23. doi: 10.1111/bjd.21678.
    PubMed    
    
    
    
31. MITTELDORF C
    Multistaining for a better understanding of lymphoma biology.
    Br J Dermatol. 2022 May 4. doi: 10.1111/bjd.21590.
    PubMed    
    
    
    March 2022
32. DOBOS G, Assaf C
    Transcriptomic changes during stage progression of mycosis fungoides: from translational analyses to their potential clinical implications.
    Br J Dermatol. 2022;186:387-388.
    PubMed    
    
    
    
33. XIAO MZX, Hennessey D, Iyer A, O'Keefe S, et al
    Transcriptomic changes during stage progression of mycosis fungoides.
    Br J Dermatol. 2022;186:520-531.
    PubMed     Abstract available
    
    
    February 2022
34. VERMEER MH, Moins-Teisserenc H, Bagot M, Quaglino P, et al
    Flow cytometry for the assessment of blood tumour burden in cutaneous T-cell lymphoma: towards a standardised approach.
    Br J Dermatol. 2022 Feb 14. doi: 10.1111/bjd.21053.
    PubMed     Abstract available
    
    
    
35. FALKENHAIN-LOPEZ D, Fulgencio-Barbarin J, Puerta-Pena M, Montero-Menarguez J, et al
    Single-centre experience of using pegylated liposomal doxorubicin as maintenance treatment in mycosis fungoides.
    Br J Dermatol. 2022;186:363-365.
    PubMed    
    
    
    January 2022
36. KEMPF W, Petrella T, Willemze R, Jansen P, et al
    Clinical, histopathological and prognostic features of primary cutaneous acral CD8+ T-cell lymphoma and other dermal CD8+ cutaneous lymphoproliferations - Results of an EORTC Cutaneous Lymphoma Group Workshop.
    Br J Dermatol. 2022 Jan 5. doi: 10.1111/bjd.20973.
    PubMed     Abstract available
    
    
    
37. BLANCHARD G, Guenova E
    Mogamulizumab-associated rash (MAR) mars its efficacy in the treatment of cutaneous lymphoma.
    Br J Dermatol. 2022;186:15-16.
    PubMed    
    
    
    November 2021
38. PAPADAVID E, Kapniari E, Pappa V, Nikolaou V, et al
    Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and Sezary syndrome with variable CD30 positivity.
    Br J Dermatol. 2021;185:1035-1044.
    PubMed     Abstract available
    
    
    
39. MOYAL L, Arkin C, Gorovitz-Haris B, Querfeld C, et al
    Mycosis fungoides-derived exosomes promote cell motility and are enriched with microRNA-155 and microRNA-1246, and their plasma-cell-free expression may serve as a potential biomarker for disease burden.
    Br J Dermatol. 2021;185:999-1012.
    PubMed     Abstract available
    
    
    October 2021
40. HENDERSON BERG MH, Davison K, Popradi G
    Real-world effectiveness of brentuximab vedotin in the treatment of CD30-positive cutaneous T-cell lymphoma: A single-centre retrospective review.
    Br J Dermatol. 2021 Oct 5. doi: 10.1111/bjd.20786.
    PubMed     Abstract available
    
    
    September 2021
41. POSPISCHIL I, Guenova E
    Mycosis fungoides-derived exosomes and their microRNA-1246 cargo: a message from the skin.
    Br J Dermatol. 2021 Sep 14. doi: 10.1111/bjd.20695.
    PubMed    
    
    
    August 2021
42. TRUM NA, Zain J, Martinez XU, Parekh V, et al
    Mogamulizumab Efficacy is Underscored by its Associated Rash that Mimics Cutaneous T-cell Lymphoma: A Retrospective Single-Centre Case Series.
    Br J Dermatol. 2021 Aug 24. doi: 10.1111/bjd.20708.
    PubMed     Abstract available
    
    
    
43. HODAK E
    Is lymph node core-needle biopsy an alternative to excisional biopsy for the accurate staging of mycosis fungoides/Sezary syndrome and predicting the survival of patients?
    Br J Dermatol. 2021;185:251-252.
    PubMed    
    
    
    
44. ORTIZ-ROMERO PL
    The time for new biomarkers in mycosis fungoides/Sezary syndrome is here.
    Br J Dermatol. 2021;185:250-251.
    PubMed    
    
    
    
45. OTTEVANGER R, de Bruin DT, Willemze R, Jansen PM, et al
    Incidence of mycosis fungoides and Sezary syndrome in the Netherlands between 2000 and 2020.
    Br J Dermatol. 2021;185:434-435.
    PubMed    
    
    
    
46. CALVANI J, de Masson A, de Margerie-Mellon C, de Kerviler E, et al
    Image-guided lymph node core-needle biopsy predicts survival in mycosis fungoides and Sezary syndrome.
    Br J Dermatol. 2021;185:419-427.
    PubMed     Abstract available
    
    
    
47. DOBOS G, De Cevins C, Ly Ka So S, Jean-Louis F, et al
    The value of five blood markers in differentiating mycosis fungoides and Sezary syndrome: a validation cohort.
    Br J Dermatol. 2021;185:405-411.
    PubMed     Abstract available
    
    
    July 2021
48. GAMBICHLER T, Boms S, Hessam S, Tischoff I, et al
    Primary cutaneous anaplastic large cell lymphoma with marked spontaneous regression of organ manifestation after SARS-CoV-2 vaccination.
    Br J Dermatol. 2021 Jul 6. doi: 10.1111/bjd.20630.
    PubMed     Abstract available
    
    
    June 2021
49. SKAYEM C, Beylot-Barry M, de Masson A, Dereure O, et al
    Lymph node and visceral progression without erythroderma or blood worsening in erythrodermic cutaneous T-cell lymphoma: nine cases.
    Br J Dermatol. 2021 Jun 15. doi: 10.1111/bjd.20580.
    PubMed     Abstract available
    
    
    May 2021
50. JONAK C, Alkon N, Rindler K, Rojahn TB, et al
    Single-cell RNAseq profiling in a patient with discordant primary cutaneous B and T cell lymphoma reveals micromilieu-driven immune skewing.
    Br J Dermatol. 2021 May 21. doi: 10.1111/bjd.20512.
    PubMed     Abstract available
    
    
    
51. ZIMMERMANN C, Boisson M, Ram-Wolff C, Sadoux A, et al
    Diagnostic performance of high throughput sequencing of the T-cell receptor beta gene for the diagnosis of cutaneous T-cell lymphoma.
    Br J Dermatol. 2021 May 3. doi: 10.1111/bjd.20432.
    PubMed     Abstract available
    
    
    
52. MOLLOY K, Vico C, Ortiz-Romero PL, Scarisbrick JJ, et al
    Real-world experience of using mogamulizumab in relapsed/refractory mycosis fungoides/Sezary syndrome.
    Br J Dermatol. 2021;184:978-981.
    PubMed    
    
    
    April 2021
53. PORCU P, Nikbakht N
    New insights on treatment utilization and outcomes in early-stage mycosis fungoides.
    Br J Dermatol. 2021;184:594-595.
    PubMed    
    
    
    March 2021
54. HODAK E, Sherman S, Papadavid E, Bagot M, et al
    Should we be imaging lymph nodes at initial diagnosis of early-stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) international study.
    Br J Dermatol. 2021;184:524-531.
    PubMed     Abstract available
    
    
    August 2020
55. D'INCAN M, Ingen-Housz-Oro S, Beylot-Barry M, Joly P, et al
    Locoregional nodal extension does not impair prognosis of primary cutaneous anaplastic lymphomas.
    Br J Dermatol. 2020 Aug 18. doi: 10.1111/bjd.19495.
    PubMed     Abstract available
    
    
    May 2020
56. DANGIEN A, Ram-Wolff C, Brice P, Battistella M, et al
    Ifosfamide and etoposide in advanced-stage, relapsed or refractory primary cutaneous T-cell lymphomas.
    Br J Dermatol. 2020 May 14. doi: 10.1111/bjd.19220.
    PubMed     Abstract available
    
    
    February 2020
57. HWANG S, Johnson A, Fabbro S, Hastings J, et al
    Topical imiquimod monotherapy for indolent primary cutaneous B-cell lymphomas (PCBCL): a single-institution experience.
    Br J Dermatol. 2020 Feb 20. doi: 10.1111/bjd.18961.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.